

Biovail Reaches Settlement Agreement with OSC Staff

January 07, 2009

TORONTO, Jan 07, 2009 (BUSINESS WIRE) -- Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced it has reached a settlement agreement with the Staff of the Ontario Securities Commission (OSC) in respect of an investigation of the Company and certain former officers. The settlement agreement, which is subject to approval by the OSC, will be considered at a hearing that has been scheduled for January 9, 2009.

The investigation related to specific accounting and financial disclosure practices, as previously disclosed, that occurred between 2001 and March 2004 and resulted in a Statement of Allegations by the OSC in March 2008. Terms of the settlement agreement are confidential and will be made public if and when approved by the OSC.

The settlement does not include four individuals who were also named in the Statement of Allegations.

About Biovail Corporation

Biovail Corporation is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet medical needs in niche specialty central nervous system (CNS) markets. For more information about Biovail, visit the Company's Web site at

www.biovail.com

For further information, please contact Nelson F. Isabel at 905-286-3000 or send inquiries to ir@biovail.com

SOURCE: Biovail Corporation

Biovail Corporation Nelson F. Isabel,
(905) 286-3000 Vice-President,
Investor Relations and Corporate Communications

Investor Inquiries

ir@bauschhealth.com

877-281-6642

514-856-3855 (Canada)



[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Media inquiries

Corporate.communications@bauschhealth.com

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.

CALIFORNIA RESIDENTS: DO NOT SELL MY
PERSONAL INFORMATION

